Jay Andersen, MD
Hematology & Oncology · Portland, ORNPI 1922001023
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,321 of the $196,439 with a category attached, or 70.4%. 18 manufacturers reported payments, led by Daiichi Sankyo Inc. at 31.0% of the total. Reporting peaked in 2021 at $67,473 and has fallen 99.9% since, to $78 in 2025. Among hematology & oncology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $948.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$61K
- AstraZeneca$38K
- Seagen Inc.$28K
- Gilead$24K
- Puma Biotechnology, Inc.$24K
- Genentech USA, Inc.$7K
- plus $15K from 12 others
Across 910 payments — averaging $8910.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$4.4M
- Eli Lilly$1.4M
- Merck$838K
- Novartis$585K
- Genentech, Inc.$389K
- Sanofi US Services Inc.$176K
- plus $269K from 5 others
What the payments were for
- Consulting fees$34,88318%
- Speaking & faculty fees$138,32170%
- Travel & lodging$18,2989%
- Food & beverage$4,8532%
- Education$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 62 | $60,824 |
| AstraZeneca | 40 | $38,080 |
| Seagen Inc. | 20 | $28,318 |
| Gilead | 19 | $23,817 |
| Puma Biotechnology, Inc. | 28 | $23,643 |
| Genentech USA, Inc. | 7 | $6,821 |
| Pfizer | 6 | $5,353 |
| Athenex Pharmaceutical Division, LLC | 2 | $2,750 |
| Novartis | 4 | $2,733 |
| F. Hoffmann-la Roche AG | 5 | $1,896 |
| Merck | 4 | $1,519 |
| Astrazeneca UK Limited | 2 | $270 |
| GE HealthCare | 1 | $133 |
| Stemline Therapeutics Inc. | 1 | $120 |
| Biontech SE | 1 | $79 |
| Astellas Pharma US Inc | 2 | $38 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$77,705
- TUKYSA$28,204
- Trodelvy$23,415
- Nerlynx$23,172
- Herceptin$6,434
- Kadcyla$3,453
- TECENTRIQ$3,314
- Oral Paclitaxel$2,750
- Encequidar$2,750
- PIQRAY$2,620
- LYNPARZA$2,498
- Non-Covered Product$1,896
- IBRANCE$1,188
- KEYTRUDA$132
- Orserdu$120
How this compares
$196,439 in reported general payments places this provider in the 95th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 28 | $434,279 |
| VerzenioAbemaciclib | 25 | $367,298 |
| LenvimaLenvatinib Mesylate | 11 | $268,654 |
| AfinitorEverolimus | 12 | $230,183 |
| KisqaliRibociclib Succinate | 14 | $214,497 |
| Lenalidomide | 24 | $208,240 |
| TagrissoOsimertinib Mesylate | 11 | $178,365 |
| PromactaEltrombopag Olamine | 12 | $87,403 |
| EliquisApixaban | 45 | $33,972 |
| Letrozole | 267 | $6,629 |
| Exemestane | 21 | $4,553 |
| Tamoxifen Citrate | 116 | $4,163 |
| Anastrozole | 182 | $3,338 |
| Estradiol | 22 | $1,840 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 40 | $658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisAfinitor, Kisqali, Promacta | $2,733 | $532,08338 claims |
| PfizerIbrance, Eliquis | $5,353 | $468,25173 claims |
| AstraZenecaTagrisso | $38,080 | $178,36511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Portland
- Brian DrukerPortland$1.9M
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Elie TraerPortland$72K
- Jeffrey MenashePortland$38K
- Michael HeinrichPortland$37K
- Lucy LangerPortland$18K
- Miklos SimonPortland$13K
- Alexandra SokolovaPortland$12K
- Jacqueline VukyPortland$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.